MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 14, 2006; DOI: 10.1124/mol.106.024299


0026-895X/07/7102-588-601$20.00
Mol Pharmacol 71:588-601, 2007

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.106.024299v1
71/2/588    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liao, Y.-F.
Right arrow Articles by Hu, M.-K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liao, Y.-F.
Right arrow Articles by Hu, M.-K.

Unnatural Amino Acid-Substituted (Hydroxyethyl)urea Peptidomimetics Inhibit {gamma}-Secretase and Promote the Neuronal Differentiation of Neuroblastoma Cells

Yung-Feng Liao, Bo-Jeng Wang, Wen-Ming Hsu, Hsinyu Lee, Chia-Yin Liao, Shin-Ying Wu, Hui-Ting Cheng, and Ming-Kuan Hu

Laboratory of Molecular Neurobiology, Institute of Cellular and Organismic Biology, Academia Sinica, Taipei, Taiwan (Y.-F.L., B.-J.W., S.-Y.W., H.-T.C.); School of Pharmacy, National Defense Medical Center, Taipei, Taiwan (C.-Y.L., M.-K.H.); Department of Surgery, National Taiwan University Hospital and National Taiwan University, Taipei, Taiwan (W.-M.H.); and Department of Life Science and Institute of Zoology, National Taiwan University, Taipei, Taiwan (H.L.)

{gamma}-Secretase, exhibiting characteristics of aspartyl protease, mediates the intramembranous proteolysis of beta-amyloid precursor protein (APP) and Notch, and it is considered to be a prime pharmacological target in the development of therapeutics for Alzheimer's disease (AD). To identify compounds that block {gamma}-secretase-mediated proteolysis, we used a highly sensitive cell-based reporter gene assay for {gamma}-secretase in which Gal4/VP16-tagged C99-APP was expressed as the immediate substrate of {gamma}-secretase, and Gal4/VP16-tagged APP intracellular domain released by the {gamma}-secretase cleavage then activated the expression of the Gal4-driven luciferase reporter gene. Using this reporter assay, we demonstrated that the newly synthesized (hydroxyethyl)urea peptidomimetics, which contain unnatural amino acid moieties at positions P1' and/or P3', can effectively inhibit {gamma}-secretase activity and significantly reduce Abeta production. The {gamma}-secretase-dependent S3 cleavage of Notch was also consistently blocked by these (hydroxyethyl)ureas as evidenced by the decreased generation of the Notch intracellular domain, a prerequisite for the activation of Notch signaling. The inhibition of Notch signaling by active Jia compounds efficiently promotes the neuronal differentiation of neuroblastoma cells, intervening in tumorigenesis and the malignancy of neuroblastomas. Our results suggest that (hydroxyethyl)urea peptidomimetics containing unnatural amino acid substitutions could represent a novel class of {gamma}-secretase inhibitors with enhanced stability, providing the basis for the further development of effective therapeutics for AD and neuroblastomas.


Received March 9, 2006; accepted November 14, 2006

Address correspondence to: Dr. Yung-Feng Liao, Institute of Cellular and Organismic Biology, Rm 238, Academia Sinica, 128 Academia Rd. Sec. 2, Taipei 115, Taiwan. E-mail: yliao{at}sinica.edu.tw







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics